Adagene(US:ADAG) Jin Rong Jie·2025-08-21 13:40Group 1 - The core viewpoint of the article highlights the financial performance and market position of Tianyan Pharmaceutical (ADAG), which is focused on developing innovative cancer immunotherapies using proprietary antibody technology [1] - As of August 21, Tianyan Pharmaceutical's stock opened at $2.15 per share, reflecting a 3.86% increase, with a total market capitalization of $101 million [1] - Financial data indicates that for the year ending December 31, 2024, the company's total revenue is projected to be $103,200, representing a significant year-over-year decrease of 99.43% [1] Group 2 - The company reported a net loss attributable to shareholders of $33.42 million, which is a 76.41% decrease compared to the previous year [1] - Tianyan Pharmaceutical is a biopharmaceutical company in the clinical product development stage, leveraging a platform-driven approach to discover and develop novel cancer immunotherapies [1] - The company utilizes a combination of computational biology and artificial intelligence to create new antibodies with high safety and efficacy, aiming to provide solutions for cancer patients [1]